brokerbase

About tradingpattern.net

The movement of a security's price over a specific time period.

dedicated to value creation and applying the scientific method in finance

Search


www.brokerbase.ch network

WP-Cumulus by Roy Tanck and Luke Morton requires Flash Player 9 or better.

mkm qualcomm ¤ vrml wedbush ¤ edmc downgrade stan ¤ market maker id ¤ qliktech morgan stanley jefferies ¤ rimm downgrade ¤ stifel nicolaus intel ¤ intc downgrade ¤ stifel nicolaus upgrades nuva ¤ credit suisse verisign ¤ wedbush vermillion ¤ citrix.atlasair.com ¤ us durables chart ¤ convergys ¤ biologic equity research delcath ¤ nasdaq:rbcn ¤ lallf google finance ¤ penn west citrix ¤ citrix.atlas air ¤ pennwest citrix ¤ recommandation outperform ¤ mkm partners qualcomm ¤ penn west citrix login ¤ kroger contact ¤ stifel nicolaus intc ¤ http://www.tradingpattern.net/2010/09/03/stocks-gain-for-fourth-straight-day-dow-sp-notch-first-positive-week-since-early-august/ ¤ phoenix solar ag ¤ market maker bpsg ¤ www.citrixatlasair.com ¤
lallf ¤ qliktech ¤ dow ¤ intel ¤ stanley ¤ credit ¤ energy ¤ buy ¤ securities ¤ ladenburg ¤ research ¤ for ¤ pennwest ¤ longbow ¤ chart ¤ hold ¤ maker ¤ capital ¤ 2010 ¤ upgrade ¤ oppenheimer ¤ equity ¤ google ¤ finance ¤ ubs ¤ market ¤ rating ¤ intc ¤ renhe ¤ stifel ¤ jefferies ¤ the ¤ upgraded ¤ west ¤ stock ¤ ratings ¤ qualcomm ¤ vermillion ¤ downgrade ¤ citrix ¤ stocks ¤ wedbush ¤ nicolaus ¤ morgan ¤ mkm ¤ outperform ¤ analyst ¤ recommendation ¤ penn ¤ from ¤ downgraded ¤

www.brokerbase.ch network - market statistics

www.brokerbase.ch network - archived market statistics

www.brokerbase.ch High dividend yield stocks

Blogroll

Recent Posts

investinformer.de - TOP100 Investment Sites Wikio - Top Blog Add to Technorati Favorites Bloggeramt.de blogoscoop Blogverzeichnis - Blog Verzeichnis bloggerei.de Add to Google Listinus Toplisten

Main | »

Dendreon – DNDN +210% – first quarter winner

By Martin | April 2, 2007

A biotechnology company, engaged in the discovery, development, and commercialization of therapeutics that harness the immune system to fight cancer.

DNDN is the first quarter winner. 

The stock price surged nearly 150% on Mar. 30 after news that the U.S. Food and Drug Administration advisory committee vouched for the company’s Provenge compound – even though the prostate cancer treatment may not kill tumors. Studies suggest, however, that the drug extends peoples’ lives.

Social Bookmarks :
  • Print
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • Blogplay
  • Add to favorites
  • BlinkList
  • blogmarks
  • Blogosphere News
  • email
  • Faves
  • FriendFeed
  • FSDaily
  • LinkArena
  • LinkedIn
  • Live
  • MisterWong
  • MisterWong.DE
  • MSN Reporter
  • PDF
  • Ping.fm
  • Reddit
  • RSS
  • SheToldMe
  • Technorati
  • ThisNext
  • Twitter
  • Webnews.de
  • Webride
  • Wikio
  • Yahoo! Bookmarks
  • Yahoo! Buzz
  • Yigg

Topics: Healthcare | No Comments »

Trackback URL for this post: http://www.tradingpattern.net/2007/04/02/dendreon-dndn-150-first-quarter-winner/trackback/

Comments

You must be logged in to post a comment.